Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

AbbVie Inc., profitability ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The profitability profile demonstrates a period of relative stability followed by a significant contraction in margins and returns, with a partial recovery in gross profitability toward the end of the observed period. While top-line efficiency recovered, bottom-line profitability and asset utilization show a sustained downward trajectory.

Gross Profit Margin
The gross profit margin remained stable between 69% and 70% throughout 2022. A downward trend emerged in 2023, reaching a trough of 62.28% by March 2024. Following this decline, a steady recovery is observed, with the margin returning to its historical baseline of approximately 70% by the end of 2024 and maintaining that level through March 2026.
Operating and Net Profit Margins
Operating margins exhibited a general decline, falling from peaks of 32.68% in early 2022 to a low of 15.16% in September 2025, despite a brief recovery to 24.65% in December 2025. Net profit margins showed a more severe and consistent erosion, dropping from over 20% in 2022 to a low of 4.00% in September 2025. The widening gap between gross and net margins suggests an increase in operating expenses, interest, or tax burdens over time.
Return on Assets (ROA)
A persistent downward trend is evident in the return on assets. ROA declined from 8.71% in March 2022 to 2.66% by March 2026. This consistent decay indicates a diminishing efficiency in utilizing the total asset base to generate net income.
Return on Equity (ROE)
Return on equity displayed high volatility. After an initial decline from 86.24% in June 2022 to 46.94% in December 2023, the ratio surged aggressively throughout 2024, peaking at 295.42% in March 2025. Given that net profit margins were simultaneously declining, this spike suggests a significant reduction in shareholder equity, likely due to aggressive share buybacks or increased leverage, rather than an increase in operational profitability.

Return on Sales


Return on Investment



Gross Profit Margin

AbbVie Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Gross margin
Net revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Gross profit margin = 100 × (Gross marginQ1 2026 + Gross marginQ4 2025 + Gross marginQ3 2025 + Gross marginQ2 2025) ÷ (Net revenuesQ1 2026 + Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibits a distinct V-shaped trajectory over the analyzed period, characterized by initial stability, a significant contraction through 2023, and a subsequent recovery to baseline levels by late 2024 and 2025.

Revenue and Gross Margin Volume
Net revenues demonstrate a general upward trend despite quarterly fluctuations, increasing from 13,538 million in March 2022 to a peak of 16,618 million by December 2025. The gross margin in absolute terms mirrors this growth, peaking at 12,066 million in the same period, indicating that the company successfully scaled its production and sales volume over the multi-year span.
Gross Profit Margin Percentage Trends
The margin percentage remained stable between 69.4% and 70.5% from March 2022 through March 2023. However, a period of margin compression began in June 2023, leading to a sharp decline that bottomed out at 62.28% in March 2024. This represents a contraction of approximately 7.25 percentage points from the 2022 average.
Recovery and Stabilization Phase
Following the trough in early 2024, a consistent recovery is observed. The gross profit margin rose to 67.21% by September 2024 and returned to the 70% threshold by December 2024. For the remainder of the period, including the forecasts through March 2026, the margin stabilized between 69.7% and 70.9%, effectively restoring the profitability levels seen prior to the 2023 decline.

Operating Profit Margin

AbbVie Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Operating earnings
Net revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Operating profit margin = 100 × (Operating earningsQ1 2026 + Operating earningsQ4 2025 + Operating earningsQ3 2025 + Operating earningsQ2 2025) ÷ (Net revenuesQ1 2026 + Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibits a general downward trajectory over the analyzed period, characterized by an initial phase of stability, a period of significant contraction, and a subsequent partial recovery.

Initial Stability Phase (March 2022 – December 2022)
During the first year of the period, operating profit margins remained relatively stable and robust, fluctuating within a narrow range between 30.33% and 32.68%. This period represents the peak profitability window within the dataset, coinciding with operating earnings that peaked at 5,502 million US$ in December 2022.
Margin Erosion and Contraction (March 2023 – December 2024)
A consistent decline in profitability is observed starting in early 2023. The margin dropped from 28.49% in March 2023 to a low of 16.22% by December 2024. This contraction occurred despite a general upward trend in net revenues, which grew from 12,225 million US$ in March 2023 to 15,102 million US$ in December 2024, suggesting that operating expenses grew at a faster rate than revenue growth.
Recovery and Stabilization (March 2025 – March 2026)
Following the trough in late 2024, the operating profit margin entered a recovery phase. Although volatility persisted—highlighted by a dip to 15.16% in September 2025—the margin climbed to 24.65% by December 2025. The period concludes with a stabilization of the margin at 24.41% in March 2026, though this remains significantly lower than the levels maintained in 2022.


Net Profit Margin

AbbVie Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Net revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Net profit margin = 100 × (Net earnings attributable to AbbVie Inc.Q1 2026 + Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025) ÷ (Net revenuesQ1 2026 + Net revenuesQ4 2025 + Net revenuesQ3 2025 + Net revenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


A comprehensive analysis of the net profit margin reveals a sustained and significant downward trajectory over the observed period. Despite a general increase in net revenues, which grew from 13,538 million USD in March 2022 to a peak of 16,618 million USD in December 2025, the company's ability to translate these top-line gains into bottom-line profitability has deteriorated substantially.

Profitability Phase Analysis
The period from March 2022 to December 2022 was characterized by relative stability and high profitability, with net profit margins consistently maintaining levels above 20%, peaking at 23.19% in September 2022.
A sharp inflection point occurred in March 2023, where the margin dropped to 13.37%. Although a brief recovery to 15.50% was observed in June 2023, this marked the beginning of a long-term erosive trend.
From September 2023 through March 2026, margins entered a state of consistent decline, falling into single digits and reaching a period low of 4.00% in September 2025 before slightly recovering to 5.79% by the end of the series.
Revenue and Earnings Divergence
A notable disconnect is observed between revenue growth and net earnings. While net revenues trended upward, net earnings exhibited extreme volatility and an overall downward trend. This is most evident in December 2024, where a revenue peak of 15,102 million USD coincided with a net loss of 22 million USD, resulting in a margin of 7.59% (indicating significant non-operating losses or extraordinary expenses during that specific quarter).
Margin Erosion Summary
The net profit margin contracted from a high of 23.19% to a final value of 5.79%, representing a total reduction of 17.4 percentage points. This indicates a systemic increase in operating costs, tax burdens, or interest expenses that have outpaced revenue growth over the multi-year period.


Return on Equity (ROE)

AbbVie Inc., ROE calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Stockholders’ equity (deficit)
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
ROE = 100 × (Net earnings attributable to AbbVie Inc.Q1 2026 + Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025) ÷ Stockholders’ equity (deficit)
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial trajectory between March 2022 and March 2026 is characterized by a significant contraction in stockholders' equity, which fundamentally alters the interpretation of the Return on Equity (ROE) metric. While net earnings exhibit considerable quarterly volatility, the consistent decline in the equity base drives an artificial inflation of profitability ratios before the equity position transitions into a deficit.

Stockholders' Equity Trend
A sustained downward trend in stockholders' equity is observed, falling from 16,283 million US$ in March 2022 to 3,325 million US$ by December 2024. This erosion accelerates in 2025, with the company entering a deficit position of 183 million US$ in June 2025, which further expands to a deficit of 6,656 million US$ by March 2026.
Net Earnings Volatility
Net earnings demonstrate significant fluctuations throughout the period. Highs were recorded in early 2022, followed by a sharp decline to 239 million US$ in March 2023. Earnings remained unstable through 2024, including a negative result of 22 million US$ in December 2024, before rebounding in early 2025.
Return on Equity (ROE) Dynamics
ROE initially remained high, fluctuating between 68.60% and 86.24% during 2022. A moderate decline occurred through 2023, reaching a period low of 46.94% in December 2023. However, a sharp reversal is noted starting in March 2024, with ROE climbing rapidly to 128.66% by December 2024 and peaking at 295.42% in March 2025.
Analysis of Ratio Distortion
The surge in ROE during 2024 and early 2025 is not attributable to a proportional increase in net earnings, but rather to the precipitous decline in the equity denominator. This mathematical effect creates a misleading appearance of increased efficiency. Following the transition to negative stockholders' equity in June 2025, the ROE metric ceases to provide meaningful analytical value, corresponding with the absence of calculated ratios for the final periods.

Return on Assets (ROA)

AbbVie Inc., ROA calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings attributable to AbbVie Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
ROA = 100 × (Net earnings attributable to AbbVie Inc.Q1 2026 + Net earnings attributable to AbbVie Inc.Q4 2025 + Net earnings attributable to AbbVie Inc.Q3 2025 + Net earnings attributable to AbbVie Inc.Q2 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibits a significant long-term downward trend, characterized by a transition from high efficiency in 2022 to a period of sustained contraction and volatility through early 2026. While the asset base remained relatively stable, the erosion of ROA is primarily attributable to the increased volatility and general decline in quarterly net earnings.

Initial Stability and Peak Performance (2022)
During 2022, the ROA maintained a strong profile, fluctuating within a narrow high range between 8.53% and 9.49%. This period represents the peak of asset utilization efficiency, supported by substantial quarterly net earnings that reached as high as 4,490 million US dollars in the first quarter.
Period of Rapid Decline (2023)
A sharp correction occurred throughout 2023, where the ROA dropped from 5.64% in March to 3.61% by December. This decline suggests a decoupling between the company's asset base and its ability to generate proportional net income, marking a transition toward a lower efficiency baseline.
Sustained Contraction and Minimums (2024–2026)
From March 2024 through March 2026, the ROA entered a phase of sustained depression, generally remaining below 4%. The metric reached its lowest point of 1.78% in September 2025. This period is marked by extreme earnings instability, including a quarterly net loss of 22 million US dollars in December 2024, which further suppressed the return profile.
Correlation Between Earnings and Asset Base
The downward trajectory of the ROA is not driven by an expansion of the asset base, which remained relatively range-bound between approximately 133 billion and 148 billion US dollars. Instead, the decline is directly correlated with the degradation of net earnings, which moved from consistent multi-billion dollar quarters to more erratic and lower nominal values.